RxDoctor Payments Data

Kristin Bagley, MD

Family Medicine · New Palestine, INNPI 1710971734

Payments from drug & device makers

$299in general payments, 2019–2025

Across 21 payments — averaging $14.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$62
  • Pfizer$60
  • Eisai Inc.$25
  • Johnson & Johnson$25
  • AbbVie$23
  • Nalpropion Pharmaceuticals LLC$22
  • plus $84 from 6 others

What the payments were for

  • Food & beverage$299100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$299 in reported general payments places this provider in the 40th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$156,143
Medicare patients
264
Services billed
2,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide104$123,934
JanuviaSitagliptin Phosphate52$64,030
EliquisApixaban64$60,790
OzempicSemaglutide30$50,043
JardianceEmpagliflozin33$39,736
FarxigaDapagliflozin Propanediol29$34,682
Soliqua 100-33Insulin Glargine/Lixisenatide16$29,703
XareltoRivaroxaban27$29,349
TrulicityDulaglutide27$26,322
VraylarCariprazine Hcl15$22,300
Xultophy 100-3.6Insulin Degludec/Liraglutide12$22,121
LinzessLinaclotide33$22,027
MyrbetriqMirabegron22$18,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,822
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$11,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$150,256131 claims
Novo NordiskOzempic, Xultophy 100-3.6$62$72,16442 claims
PfizerEliquis$60$60,79064 claims
AbbVieVraylar, Linzess, Synthroid$23$48,806108 claims
Johnson & JohnsonXarelto$25$29,34927 claims
Astellas Pharma US IncMyrbetriq$20$18,45322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in New Palestine

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →